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Recombinant soluble trimeric influenza A virus (IAV) hemagglutinin (sHA3) has proven an effective vaccine antigen against
IAV. Here, we investigate to what extent the glycosylation status of the sHA3 glycoprotein affects its immunogenicity. Different
glycosylation forms of subtype H5 trimeric HA protein (sH53) were produced by expression in insect cells and different mamma-
lian cells in the absence and presence of inhibitors of N-glycan-modifying enzymes or by enzymatic removal of the oligosaccha-
rides. The following sH53 preparations were evaluated: (i) HA proteins carrying complex glycans produced in HEK293T cells; (ii)
HA proteins carryingMan9GlcNAc2 moieties, expressed in HEK293T cells treated with kifunensine; (iii) HA proteins containing
Man5GlcNAc2 moieties derived fromHEK293S GnTI() cells; (iv) insect cell-produced HA proteins carrying paucimannosidic
N-glycans; and (v) HEK293S GnTI() cell-produced HA proteins treated with endoglycosidase H, thus carrying side chains com-
posed of only a singleN-acetylglucosamine each. The different HA glycosylation states were confirmed by comparative electro-
phoretic analysis and bymass spectrometric analysis of released glycans. The immunogenicity of the HA preparations was stud-
ied in chickens andmice. The results demonstrate that HA proteins carrying terminal mannose moieties induce significantly
lower hemagglutination inhibition antibody titers than HA proteins carrying complex glycans or singleN-acetylglucosamine
side chains. However, the glycosylation state of the HA proteins did not affect the breadth of the antibody response as measured
by an HA1 antigen microarray. We conclude that the glycosylation state of recombinant antigens is a factor of significant impor-
tance when developing glycoprotein-based vaccines, such as recombinant HA proteins.
Influenza A viruses (IAVs) are important human and animalpathogens. Because of their wide spread and their presence in
animal reservoirs, eradication of IAV is not possible. Vaccination
provides the most effective way to control IAVs and to protect
against IAV infection and disease. Despite the efficacy of the ap-
proved influenza vaccines, issues related to, among other things,
their production and safety call for alternative approaches, as has
been reviewed elsewhere (12, 28).
As protection against influenza virus infection and disease cor-
relates with serum anti-hemagglutinin (HA) (23) antibody levels,
recombinant HA proteins may prove to be attractive vaccine an-
tigens. Recombinant HA glycoproteins can be produced using
safe, quality controlled, and scalable conditions (10) without the
need for virus cultivation. Furthermore, adverse reactions may be
limited, as the HA preparations can be highly purified and do not
contain egg contaminants. In addition, recombinant HA proteins
can be manufactured with short lead times, allowing an acceler-
ated response to emerging IAV strains.
Expression of recombinant HA proteins in higher eukaryotic
expression systems is likely to result in superior antigens com-
pared to other expression systems, as folding and trimerization of
the HA protein are known to depend on multiple co- and post-
translational modifications, including glycosylation and disulfide
bond formation. Consistently, mammalian-cell-derived HA tri-
mers have been shown to induce higher levels of neutralizing an-
tibodies than their monomeric counterparts (37). We and others
have previously demonstrated the efficacy of recombinant tri-
meric HA protein preparations from insect ormammalian cells to
protect against IAV infection and disease (4, 5, 17, 34, 36).
N-linked glycosylation is essential for proper folding, oligo-
merization, and transport of the HA protein (13). In addition,
glycosylation may affect cleavage of the HA protein (8) and HA-
receptor binding and fusion (21, 22). Loss of N-glycan sites neigh-
boring the receptor-binding site or enzymatic truncation of the
N-glycan structureswere both shown to result in increased affinity
of HA for receptors (21). We and others recently showed that HA
proteins that differ only in their glycosylation status, as a result of
different production or processing conditions, possess different
receptor fine specificities (9, 34). Furthermore, HA-linked oligo-
saccharidesmay function inmasking antigenic regions, while they
may also serve as a target for recognition of IAV by the innate
immune system (25, 31). Antibodies raised against HA protein
bearing only a single N-acetylglucosamine (GlcNAc) at each gly-
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cosylation site were reported to show better binding affinity and
IAVneutralization activity than antibodies raised againstHA con-
taining complex glycans (34).
In view of the apparent importance of glycosylation for HA
structure, functioning, and antigenicity, we decided to compare
the immune responses induced by recombinant soluble trimeric
HA proteins of the H5 subtype (sH53) that differ in their glycosy-
lation states. The results show that HA proteins carrying N-gly-
cans with terminal mannoses induce lower antibody titers than
those carrying complex N-glycans or single GlcNAc residues. HA
proteins carrying single GlcNAc side chains induced similar or
higher antibody responses, depending on the specific H5 protein
used. The HA glycosylation state did not appear to affect the
breadth of the antibody response, as similar reactivities were ob-
served against different HA1 domains, regardless of the glycosyla-
tion state of the immunogens used.
MATERIALS AND METHODS
Genes and expression vectors. cDNA clones corresponding to residues
18 to 523 (H3 numbering) of HA from A/reassortant/NIBRG-14 (Viet
Nam/1194/2004 Puerto Rico/8/1934) (H5N1) (GenBank accession no.
ACU65077.1) and A/Mallard/Denmark/64650/03 (H5N7) (GenBank ac-
cession no. AAT07996.1) were synthesized using human-preferred
codons by GenScript USA Inc. H5 derived from the H5N7 virus (desig-
nated sH53
N7) lacks a glycosylation site on the globular head and has 94%
sequence identity to H5 derived from H5N1 virus (designated sH53
N1).
Cloning of the H5 sequences into the appropriate expression vector was
done as described previously (5). Briefly, cDNAwas cloned into the pCD5
expression vector for efficient expression in mammalian cells or into the
pMT-Bip vector (Invitrogen) for expression in Schneider S2 cells. The
HA-encoding cDNAwas cloned in frame with DNA sequences coding for
a signal sequence, an artificial GCN4 isoleucine zipper trimerizationmotif
(RMKQIEDKIEEIESKQKKIENEIARIKK), and Strep-tag II (WSHPQ
FEK; IBA, Germany).
Protein expression and purification. pCD5 expression vectors con-
taining the HA ectodomain-encoding sequences were transfected into
HEK293T and HEK293S GnTI() cells (26) as described previously (5).
HAproteins secreted by the cells were purified using Strep-Tactin Sephar-
ose beads according to the manufacturer’s instructions (IBA, Germany).
When indicated, HA trimers bound to Strep-Tactin beads were treated
with endoglycosidase H (EndoH) for 3 h at 37°C (2 U/ml), followed by
three washing steps prior to elution of the protein from the beads. Dro-
sophila Schneider S2 cells were cotransfectedwith pMT-Bip vector encod-
ing the HA ectodomain and pCoBlast using Cellfectin in a 19:1 ratio, and
stable cell lines were selected according to the manufacturer’s protocols
(Invitrogen) as described previously (9). HA proteins were purified as
described above. HA protein expression and secretion were confirmed by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
followed byWestern blotting using amouse anti-Strep-tag antibody (IBA,
Germany). The concentration of purified protein was determined by us-
ing aNanodrop 1000 spectrophotometer (Isogen Life Sciences) according
to the manufacturer’s instructions.
Characterization of recombinant HA. Oligomerization of the sH53
proteins was confirmed by Blue Native PAGE as described previously (9).
For dendritic cell-specific intercellular adhesion molecule-3-grabbing
nonintegrin (DC-SIGN)-binding experiments, 96-well Nunc MaxiSorp
plates were coatedwith 5g/mlHA for 16 h at 4°C in PBS. The plates were
blocked with a solution of 3% bovine serum albumin (BSA) and 0.1%
Tween 20 in phosphate-buffered saline (PBS) for 2 h at room temperature
(RT), followed by three washes with 0.05% Tween 20 in PBS. Subse-
quently, serially dilutedDC-SIGN–Fc (R&DSystems)was added for 2 h at
RT, followed by three washes with 0.05% Tween 20 in PBS. Horseradish
peroxidase (HRP)-labeled goat anti-human IgGwas added for 1 h at RT at
a 1:1,000 dilution, followed by three washes with 0.05% Tween 20 in PBS.
Peroxidase activity was visualized using tetramethylbenzidine substrate
(BioFX) and an enzyme-linked immunosorbent assay (ELISA) reader
(EL-808 [BioTEK]), reading the optical density (OD) at 450 nm.The sialic
acid-binding activity of the sH53 protein preparations was assessed by
using a fetuin solid-phase assay as described previously (9).
Glycan release, purification, labeling, and mass spectrometry. The
sH53 proteins were treated with the glycosidase PNGaseF (NEB) accord-
ing to the manufacturer’s protocol. The N-glycan mixture released by the
PNGaseF treatment was applied to a C18 RP cartridge (500 mg; JT Baker,
Phillipsburg, NJ). The combined flowthrough and wash fractions (2 ml
10% acetonitril [AcN] and 4 ml water) of these cartridges were subse-
quently applied to carbon cartridges (150 mg Carbograph; Grace, Deer-
field, IL). After a wash with 6ml water, glycans were eluted with 3ml 25%
AcN and 3 ml 50% AcN containing 0.1% trifluoroacetic acid (TFA). The
purified N-glycans were subsequently labeled with the fluorophore
2-aminobenzoic acid (2-AA), as described elsewhere (27). The labeled
glycans in 75% AcN were loaded on Biogel P10 (Bio-Rad Hercules, CA)
conditioned with 80%AcN. After a wash with 80%AcN, the glycans were
eluted with water and analyzed with an Ultraflex II matrix-assisted laser
desorption ionization–time-of-flight (MALDI-TOF) mass spectrometer
(Bruker Daltonics, Bremen, Germany) operating in the negative-ion re-
flectron mode. 2,5-Dihydroxybenzoic acid (DHB; Bruker Daltonics, Bre-
men, Germany) was used as a matrix. When indicated, 2-AA-labeled gly-
cans (4 l) were treated with beta-galactosidase from jackbean (45 mU;
Prozyme,Hayward, CA) in 60l 250mMsodium citrate buffer for 24 h at
37°C. The digestion products were purified using a Ziptip C18 column
(Millipore, Billerica,MA) following themanufacturer’s instructions. Gly-
cans were eluted directly to a MALDI target plate with 10 mg/ml DHB in
50% AcN containing 0.1% TFA and analyzed in the negative-ion reflec-
tron mode.
Immunization experiments. Animal studies were conducted at the
Central Veterinary Institute (CVI), Lelystad, The Netherlands, and at the
Central Laboratory Animal Research Facility (CLARF) Utrecht after ap-
proval by the appropriate animal ethics committees. Thirty 1-day-old
layer hens (white Leghorn) were purchased from a local breeder. The
chickens had been vaccinated against Newcastle disease virus and infec-
tious bronchitis virus at the age of 1 day, according to the farm’s routine,
andwere raised in theCVI’s animal facility. At the age of 6weeks, the birds
were allocated to 3 experimental groups of 10 birds each. The animals
were immunized twice (on days 0 and 21) by intramuscular (i.m.) injec-
tion of 2 g sH53 antigen adjuvanted with Stimune (Prionic). As a con-
trol, one group wasmock vaccinated twice (on days 0 and 21) with PBS in
Stimune. Bloodwas taken before the second vaccination and 3weeks after
the second vaccination. For the mouse experiments, female 9-week-old
C57BL/6mice obtained fromCharles River Laboratorieswere immunized
twice (on days 0 and 21) by i.m. injection (0.05 ml) of 4 g sH53 antigen
adjuvanted with Stimune. Six animals per group were used. As a control,
in each experiment, one group of mice was mock vaccinated twice. Blood
was taken before and 3 weeks after the second vaccination.
HI assay. Vibrio cholerae neuraminidase (VCNA)-treated and heat-
inactivated immune sera from mice and chicken blood samples were
tested for hemagglutination inhibition (HI) activity with 8 or 4 hemag-
glutinating units (HAU) of homologous antibody-complexed sH53 pro-
duced inHEK293SGnTI() cells as described previously (5). To this end,
the recombinant proteins were precomplexed with anti-Strep tag and
anti-mouse antibodies as described previously (5), mixed with limiting
dilutions of mouse sera, and incubated with 0.5% chicken red blood cells
in PBS containing 1% BSA. Antibody titers were expressed as the recip-
rocal of the highest serum dilution showing HI.
ELISA. IgG1 antibody titers against sH53 produced in HEK293T cells
were determined by using a sH53-specific ELISA. To this end, 96-well
Nunc MaxiSorp plates were coated with 100 l of 2-g/ml sH53 per well
and incubatedwith limiting dilutions ofmouse sera. After extensivewash-
ing, the plates were incubated with goat-anti-IgG1mouse antibodies con-
jugated with HRP. Peroxidase activity was visualized using tetramethyl-
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benzidine substrate (bioFX) and an ELISA reader (EL-808 [BioTek]),
reading the OD at 450 nm. Wells coated with purified mouse IgG1 were
used to determine the amount of sH53-specific IgG1 present in the sera.
Suppression of pDC function. Human plasmacytoid dendritic cells
(pDCs) were isolated frombuffy coats obtained from theNewYork Blood
Center. pDCs were purified from human peripheral blood mononuclear
cells (PBMC) using a CD304 (BDCA-4)Microbead Kit (Miltenyi Biotec).
The purity of the enriched pDC population was 97%, as assessed by
CD123 and BDCA-2 staining. Freshly isolated pDCs were treated with 10
g/ml of sH53 in the presence of endotoxin-free recombinant CpG-A
(ODN2216; Invivogen) at 500 ng/ml for 18 h. RecombinantHIV-1 gp120
andHIV-1 p24 proteins (ImmunoDiagnostics Inc.) served as positive and
negative controls, respectively. Culture supernatants were collected for
quantification of alpha interferon (IFN-) by ELISA, according to the
manufacturer’s instructions (PBL Biomedical Laboratories).
HA1 antigen microarray. An HA1 antigen microarray was done as
described previously (15). Briefly, commercially availableHA1proteins of
H1, H2, H3, and H5 influenza A viruses produced in HEK293 cells and
purified by His tag purification (Immune Technology, New York, NY)
(see Fig. 7 for strain information on the HA1 antigens used) were spotted
on 16-pad nitrocellulose-coated slides (Oncyte Avid; Grace Bio-Labs,
Bend, OR). The slides were treated with Blotto blocking buffer to avoid
nonspecific binding to the nitrocellulose surface (Thermo Fisher Scien-
tific Inc., Rockford, MA), washed, and incubated with serial 4-fold dilu-
tions of serum ranging from 1:20 to 1:327,680 in Blotto containing 0.1%
Surfact-Amps 20 (Thermo Fisher Scientific Inc.). After washing, goat
anti-mouse IgG (Fc fragment specific) conjugated with Dylight 649 fluo-
rescent dye (Jackson Immuno Research,West Grove, PA) was added. The
slides were scanned using a ScanArray Gx Plus microarray scanner
(PerkinElmer), and titers were defined as the interpolated serum concen-
tration that provoked a response halfway on a concentration-response
curve between the minimum and maximum signals, as described previ-
ously (15). Titers lower than the smallest serum dilution (1:20) were set
to 20.
Statistical analysis. Significance among animal groups was analyzed
by Student’s t test or by one-way analysis of variance (ANOVA) andTukey
test after ANOVA. Differences were considered significant at a P value of
0.05.
RESULTS
HA-glycan-dependent induction of antibodies against sH53
N1.
Previously, we showed that recombinant soluble trimericHApro-
teins can protect chickens, mice, pigs, and ferrets against a (lethal)
challenge with the homologous IAV. The recombinant proteins
used to vaccinate the animals were produced inHEK293T cells (4,
17) or inHEK293SGnTI() cells, which are deficient inN-acetyl-
glucosaminyltransferase I (GnTI) activity, resulting in immature
HA glycoproteins containing Man5GlNAc2 glycans (5, 26). Dur-
ing one of these vaccination-challenge experiments in which
chickens were vaccinated with 2g sH53
N1 produced inHEK293S
GnTI() cells (5), a parallel experiment was performed in which
other chickens were vaccinated twice with the same amount of
recombinant protein produced in HEK293T cells. These recom-
binant proteins differ only in their glycosylation states. While
HEK293T cell-produced HA protein carries complex glycans, the
HA proteins made in the HEK293S GnTI() cells carry high-
mannose oligosaccharides. While none of the chickens that were
vaccinated twice with 2 g sH53
N1 died or showed symptoms
indicative of influenza-related disease after challenge by intrana-
sal/intratracheal inoculation of a lethal dose of A/Vietnam/
1194/04 virus (reference 5 and data not shown), differences were
observed in HI antibody titers, depending on the cells fromwhich
the recombinant proteins were derived (Fig. 1A). Although all
immunized animals developed appreciable HA antibody titers
both after the first vaccination and after the boost, HI titers were
significantly higher after vaccination with HEK293T cell-derived
sH53
N1 than after vaccination with HEK293S GnTI() cell-de-
rived HA protein. The mock-immunized chickens had an HI titer
below the detection limit.
To confirm and extend these observations, we switched to an-
other animal model. Thus, mice were immunized twice with 4 g
FIG 1 HA-glycan-dependent induction of antibodies against sH53
N1. (A)
Chickens (10 per group) were immunized twice with purified sH53
N1 protein
preparations produced in HEK293T cells (293T) or HEK293S GnTI() cells
(GnTI). As a control, chickens were mock treated (PBS). Blood samples were
taken 3 weeks after the first and after the second vaccinations. HI titers against
8 HAU sH53
N1 in serum for each bird are shown. (B) Mice (6 per group) were
immunized twice with sH53
N1 protein preparations produced in HEK293T
cells (293T), in HEK293T cells treated with 100MKIF (KIF), or inHEK293S
GnTI() cells (GnTI). Blood samples were taken 3 weeks after the second
immunization. HI titers against 8 HAU sH53
N1 in serum for each mouse are
shown. (A and B) The horizontal lines represent the geometric means per
group. Significant differences between groups (panel A, Student’s t test; panel
B, ANOVA) are indicated as follows: *, P 0.05; **, P 0.01; ***, P 0.001.
(C) Purified sH53
N1 protein preparations were analyzed by SDS-PAGE, fol-
lowed by Western blotting. Where indicated, the proteins were treated with
EndoH or PNGaseF prior to electrophoresis. The recombinant proteins were
detected using a mouse anti-Strep tag antibody (29).
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of purified sH53
N1 produced in HEK293T or in HEK293S
GnTI() cells. In addition, another group was taken along, in
which mice were immunized with sH53
N1 produced in HEK293T
cells in the presence of 100 Mkifunensine (KIF). KIF is a potent
and selective inhibitor of class I -mannosidases (11). Both the
HEK293S GnTI() cell-produced HA protein and the HA pro-
tein produced inHEK293T cells in the presence of KIF carry high-
mannose glycans containing either 5 or 9 mannoses, respectively.
Three weeks after the second immunization, blood samples were
taken and HA antibody titers in the serum were determined. The
results are shown in Fig. 1B. Again, the HA proteins expressed in
HEK293T cells in the absence of KIF and thus containing complex
glycans induced the highest HI antibody titer. The mice immu-
nized with the protein preparations containing the high-mannose
glycans displayed significantly lowerHI antibody titers. No appre-
ciable HI antibody titers were detected after mock immunization.
HI antibody titers measured in mice were previously shown to
correlate with protection from lethal influenza virus infection (5).
To confirm their different glycosylation states, the protein
preparations were subjected to gel electrophoresis (Fig. 1C). The
sH53
N1 proteins carrying the high-mannose glycans migrated
somewhat faster in the gel than the HEK293T cell-produced HA,
with the HEK293S GnTI() cell-produced HA protein, which
carries the smallest N-glycan side chains, demonstrating the high-
est electrophoretic mobility. As expected, only the proteins with
high-mannose oligosaccharides were sensitive to EndoH, in
agreementwith the known specificity of this endoglycosidase (18).
When the HA proteins derived from the different expression sys-
tems were treated with PNGaseF, an enzyme that removes all N-
linked glycans, they migrated with similar mobilities in the gel,
consistent with the HA proteins having identical protein back-
bones and only differing in their N-linked glycosylation.
HA-glycan-dependent induction of antibodies against
sH53
N7. Next, we investigated whether the detrimental effect of
terminal mannose moieties on the immune response was related
to the specific HA or whether it could also be observed by using a
different HA protein. Therefore, soluble trimeric H5 from a dif-
ferent H5 virus, H5N7 (sH53
N7), was prepared. This H5 protein
carries one oligosaccharide side chain less than sH53
N1 (Fig. 2). In
addition, we expanded our set of protein preparations by includ-
ing HEK293S GnTI() cell-produced HA protein treated with
EndoH, which results in an HA protein that carries a monosac-
charide GlcNAc side chain, and HA protein produced in S2 insect
cells, which carries paucimannosidic N-glycans with 3 mannose
moieties (14). The glycoproteins were analyzed by gel electropho-
resis, as shown in Fig. 3. The electrophoretic mobilities of the
glycoproteins differed according to their differential glycosyla-
tion. Thus, while HEK293T cell-produced HA displayed the
lowest electrophoretic mobility, consistent with sH53
N7 carrying
large, complex glycans, the highest mobility was observed for the
EndoH-treated protein, which carries only single GlcNAc resi-
dues. The terminal-mannose-containingHAproteinsmigrated in
line with the sizes of their glycans [9, 5, and 3 mannoses for
HEK293T cell-produced HA in the presence of KIF, for HEK293S
GnTI() cell-producedHA, and for S2 cell-producedHA, respec-
tively (14)]. Of these HA glycoproteins, the H5 protein produced
in insect cells was resistant to treatment with EndoH, as EndoH
removes only N-linked sugars containing more than three man-
nose moieties (18). When the HA proteins were deglycosylated
using PNGaseF, they all comigrated in the gel, consistent with
having identical polypeptide backbones irrespective of the cell
type from which they originated.
To further confirm the different glycosylation states of our H5
preparations, we analyzed the interaction of sH53
N7 with DC-
SIGN, which is known to interact with carbohydrates carrying
terminal mannose moieties (35). After 96-well plates were coated
with HA, binding of DC-SIGN to HA was determined using an
ELISA-type assay. While no appreciable DC-SIGN binding was
observed withHA carrying complex glycans or single GlcNAc res-
idues, binding to HA proteins carrying terminal mannoses was
readily observed (Fig. 3B). The extent of binding of DC-SIGN to
the different terminal mannose-containing HA preparations cor-
related with published data (32).
As mammalian-cell-derived HA trimers were found to induce
higher levels of neutralizing antibodies than similarly produced
monomeric HA protein (37), we also analyzed the oligomeric na-
ture of the purifiedHA proteins produced by the different expres-
sion systems by using Blue Native PAGE. As shown in Fig. 3C, all
proteins migrated at the high position in the gel that corresponds
to their trimeric nature (5). When the H5 preparations were heat
denatured, the initially trimeric HA species dissociated into
monomers. Subsequently, we demonstrated that the sH53
N7 pro-
teins are biologically active, as the different H5 preparations
displayed efficient binding to the sialylated glycoprotein fetuin
(Fig. 3D), although some glycosylation-dependent differences
were observed, in agreement with our previous study (9).
Mass spectrometry. Finally, the oligosaccharides attached to
the sH53
N7 proteins were analyzed using mass spectrometry. To
this end, glycans were enzymatically released from the glycopro-
tein using PNGaseF and analyzed by MALDI-TOF mass spec-
trometry after purification and labeling with 2-AA. To each of the
peaks within the resulting spectra, amonosaccharide composition
was assigned based on the monoisotopic mass, from which a pu-
tative structure was deduced, as indicated in Fig. 4. The glycans
derived from HEK293T cell-produced HA (Fig. 4A) gave rise to a
relatively complex mass spectrum, with major signals suggesting
the presence of di-, tri- and tetra-antennary complex-type glycans
with N-acetyllactosamine [Gal(1-4)GlcNAc(1-)] antennae.
Signals representing extensions of these glycans with one or more
N-acetylneuraminic acids and/or carrying a fucose at the reduc-
ing-end GlcNAc were also observed. These putative assignments
FIG 2 Structure representation of H5 derived from H5N1 with complex N-
glycans attached at its N-glycosylation sites. The protein structure (black) was
created with Protein Data Bank ID code 2IBX, and the N-linked glycans (gray)
were modeled with Glyprot (3). For comparison, a model (labeled H5N1) is
shown in which the N-linked glycan side chain that is missing in H5 from
H5N7, compared to HA derived from H5N1, has been deleted.
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were supported by-galactosidase treatment, which led to the loss
of all nonsialylated galactoses, thereby confirming the number of
antennae in each glycan and the absence of possible linear N-
acetyllactosamine repeats (Fig. 4B). For example, the AA-labeled
fucosylated tetra-antennary glycan with the composition
Hex7HexNAc6Fuc1 (Hex, hexose; HexNAc, N-acetylhexosamine;
Fuc, fucose) observed at m/z 2,637.2 [M-H] (Fig. 4A) disap-
peared after -galactosidase treatment, giving rise to a new signal
at m/z 1,988.5 (Fig. 4B) representing the Hex3HexNAc6Fuc1 spe-
cies formed by the loss of four galactose residues from the four
N-acetyllactosamine antennae in the nontreated glycan.
The spectrum of the released N-glycans of HA produced in
HEK293T cells treated with KIF (Fig. 4C) showed only one
peak at m/z 2,002.5 [M-H], which corresponded to the high-
mannose N-glycan carrying 9 mannoses (Hex9HexNAc2), in
line with the inhibitory effect of KIF on glycan processing. The
spectrum of the HEK293S GnTI() cell-produced HA also
gave only one high-abundance signal at m/z 1,354.3 [M-H]
with the composition Hex5HexNAc2, corresponding to a high-
mannose peak carrying 5mannose moieties (Fig. 4D). This is in
agreement with expectations, since the absence of GnTI activity
prevents the addition of GlcNAc to the 1-3-linked core man-
nose, thereby blocking further processing of the glycan. The
majority of the N-glycans released from S2 cell-produced HA
were of the paucimannosidic type (Fig. 4E). Major signals with
the compositions Hex3HexNAc2Fuc1 and Hex3HexNAc2 were
observed at m/z 1,176.5 [M-H] and m/z 1,030.4 [M-H], re-
spectively, indicating the presence of the trimannosyl core gly-
can with or without a fucose linked to the innermost GlcNAc
residue. In addition, some minor signals were observed at m/z
1,014.4 [M-H] (Hex2HexNAc2Fuc1), at m/z 1,233.5 [M-H]

(Hex3HexNAc3), and at m/z 1,354.5 [M-H]
 (Hex5HexNAc2).
This observation is in line with previously reported N-glycan
structures on recombinant proteins expressed in S2 cells (14).
Induction of antibodies against sH53
N7. After having ana-
lyzed the glycosylation states of the different sH53
N7 protein prep-
arations, the HA proteins were tested for the ability to induce HI
antibodies. To this end, mice were immunized twice with the dif-
ferent HA preparations, after which the HI serum antibody titers
were determined. The results are shown in Fig. 5. In agreement
with the previous experiment, mice vaccinated with HA proteins
carrying terminal mannose moieties displayed significantly lower
HI antibody titers than mice immunized with HA proteins carry-
ing complex glycans. No apparent differences were observed in
the HI antibody titers induced by HA proteins containing glycans
with 9, 5, or fewer mannose moieties. Removal of the high-man-
nose glycans from the HA proteins produced in HEK293S
GnTI() cells by EndoH treatment appeared to result in higher
HI antibody titers, although this difference was not significant.
Very similar results were observed when HA-specific IgG1 levels
were determined using ELISA (Fig. 5B). When the data were
pooled based on the absence (HEK293T cell-produced HA and
EndoH-treated HA) or presence [HA produced in HEK293T cells
treated with KIF, HEK293S GnTI() cell-produced HA, and S2
cell-produced HA] of terminal mannose moieties, again, signifi-
cantly lower HI antibody titers and HA-specific IgG1 levels were
FIG 3 Analysis of different sH53
N7 preparations. sH53
N7 proteins produced in HEK293T cells (293T), HEK293T cells treated with KIF (KIF), or HEK293S
GnTI() cells (GnTI) or in insect S2 cells (S2), andHEK293SGnTI() cell-produced sH53
N7 treated with EndoH (EndoH)were purified and analyzed. (A) The
HA proteins were analyzed by SDS-PAGE, followed by Western blotting. The proteins were detected using a mouse anti-Strep tag antibody (29). Where
indicated, samples were treated with PNGaseF or EndoH prior to electrophoresis. (B) Binding of Fc-tagged DC-SIGN (2.5 g/well) to wells coated with the
different HA preparations (5 g/well) or with no HA protein (Mock). Binding of DC-SIGN was detected using HRP-labeled goat-anti-human IgG. (C) Blue
Native-PAGE analysis of theHAprotein preparations. The positions in the gel of the trimeric andmonomeric protein species are indicated, aswell as samples that
were denatured by heating them for 1 min at 95°C prior to electrophoresis. (D) sH53 proteins were complexed with HRP-conjugated mouse antibody directed
against the Strep tag prior to their application in a fetuin binding assay. HA-fetuin binding is shown at an HA concentration of 2.5 g/ml. Standard deviations
are indicated by the error bars.
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observed for the mice immunized with HA proteins carrying
mannose moieties (Fig. 5C and D).
Terminal-mannose-containing H5 proteins impair CpG-in-
duced IFN-productionbypDCs.Mannoses onHIVgp120have
been reported to induce immunosuppression (1, 3), and it has
been suggested that this is in part caused by suppression of den-
dritic cell (DC) function (19, 30). To examine the effects of termi-
nal-mannose-containing HAs on DC function, we treated pDCs
with sH53
N7 proteins produced in HEK293T, KIF-treated
HEK293T, HEK293S GnTI(), and S2 cells in the presence of the
TLR9 agonist CpG. As previously described, HIV gp120 sup-
pressed IFN- release by pDCs upon CpG stimulation, presum-
ably through binding to the C-type lectin receptor BDCA-2 (19)
(Fig. 6). HAs produced from KIF-treated HEK293T, GnTI(),
and S2 cells also significantly inhibited CpG-induced IFN- re-
lease, by 32%, 71%, and 36%, respectively (Fig. 6). In contrast, HA
derived from HEK293T cells and HIV-1 p24 Gag protein had no
inhibitory effect. These data suggest that HA proteins carrying
terminal mannoses, but not those carrying complex glycans, may
suppress DC function.
Comparison of HA-glycan-dependent induction of antibod-
ies against sH53
N1 and sH53
N7.Wang and coworkers recently re-
ported that antibodies raised against H5 protein bearing single
N-linkedGlcNAc side chains showed stronger binding to different
native HA proteins and stronger virus neutralization than sera
raised against H5 proteins carrying complex glycans (34). As the
FIG 4 Mass spectrometric glycan analysis of different sH53
N7 preparations. Shown are MALDI-TOF mass spectra of the N-glycans of purified sH53
N7 protein
preparations produced in HEK293T cells (A and B), HEK293T cells treated with KIF (C), HEK293S GnTI() cells (D), and insect S2 cells (E). N-glycans were
released by PNGaseF, labeled with anthranilic acid, and analyzed in negative-ion reflectron mode. All signals were labeled with monoisotopic masses, and the
structureswere deduced from the composition indicated by thismass. In the case of theHEK293T sample (A), only the 10 signalswith the highest abundancewere
labeled with assigned structures; these structures were confirmed by beta-galactosidase treatment of the HEK293T sample (B), and in each case, the number of
terminal galactose residues present is indicated. Compared to the spectrum before treatment (A), a clear loss of all galactoses not carrying N-acetylneuraminic
acid is visible, indicating a high abundance of terminal galactose. The double-headed arrows indicate a difference in fucose content. Red triangles, fucose; purple
diamonds, N-acetylneuraminic acid; yellow circles, galactose; blue squares, N-acetylglucosamine; green circles, mannose; white square, N-acetylhexosamine.
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HI serum titers ofmice immunizedwith sH53
N7 preparationswith
complex glycans were quite similar to those obtained with prepa-
rations with single GlcNAc side chains (Fig. 5A), we performed a
new experiment in which we analyzed antisera raised against dif-
ferently glycosylated sH53
N7 and sH53
N1 preparations. To this
end, mice were immunized twice with sH53
N1 or sH53
N7 prepara-
tions that carry either complex (HA produced in 293T cells) or
paucimannose (HA produced in insect cells) glycans or single
N-linked GlcNAc side chains [EndoH-treated samples from
GnTI() cells], after which the HI serum antibody titers were
determined using the homologous sH53
N1 or sH53
N7 protein. In
agreement with the previous experiments, lower HI titers were
obtained with sera from mice vaccinated with the HA proteins
carrying paucimannose glycans than from sera from mice vacci-
nated with the HA proteins carrying complex glycans, although
the differences were significant only for the sH53
N1 preparations
(Fig. 7A). Immunization of mice with HA proteins carrying single
GlcNAc residues resulted in HI titers that were comparable to
(sH53
N7) or somewhat higher than (sH53
N1) those induced by
their counterparts carrying complex glycans.
Finally, we analyzed whether the antisera raised against the
different H5 preparations differed in their reactivities against
FIG 6 Inhibition of CpG-induced IFN- production by HA. Freshly isolated
pDCs were treated with sH53
N7, produced in HEK293T, KIF-treated
HEK293T, HEK293S GnTI(), and S2 cells, in the presence of CpG. The
culture supernatants were collected after 18 h for IFN- quantification by
ELISA. The data shown are from one representative experiment out of four
independent experiments with pDCs from four different donors. Significant
differences between groups treated with the different HA protein preparations
are indicated: ***, P 0.001.
FIG 5 HA-glycan-dependent induction of antibodies against sH53
N7. (A) Mice (six per group) were immunized twice with sH53
N7 protein preparations
produced in HEK293T cells (293T), HEK293T cells treated with KIF (KIF), HEK293S GnTI() cells (GnTI), or insect S2 cells or with HEK293S GnTI()
cell-produced sH53
N7 treated with EndoH (EndoH). Blood samples were taken 3 weeks after the second immunization. HI titers against 4 HAU sH53
N7 in serum
for eachmouse are shown. (B) HA-specific IgG1 levels (g perml serum) were determined by ELISA. (C) Graph displaying the data shown in panel A pooled on
the basis of the absence [man; HEK293T cell-produced HA and EndoH-treated HA produced in HEK293S GnTI() cells] or presence [man; HA produced
in HEK293T cells treated with KIF, HEK293S GnTI() cell-produced HA, and S2 cell-produced HA] of terminal mannose residues in the sH53
N7 protein
preparations for which data are shown. (D) Similar to panel C, but showing the HA-specific IgG1 levels. The horizontal lines in the scatter dot plots represent
geometric means per group. Significant differences between groups (panels A and B, ANOVA; panels C and D, Student’s t test) are indicated as follows: *, P
0.05; **, P 0.01; ***, P 0.001.
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IAVs of various serotypes. The sera were tested using a recently
developed HA1 protein array (15) against a panel of HA1 do-
mains. In agreement with the evolutionary relationship between
the HA proteins on the array and the HA proteins used for immu-
nization (Fig. 7B), sera raised against sH53
N1 exhibited higher re-
activity against HA1 proteins derived from other H5N1 viruses
than against those fromH5N3 orH5N8 virus (Fig. 7C), while they
reacted poorly with the HA1 proteins from the H1, H2, and H3
viruses. The pattern of reactivities of the sera raised against the
sH53
N7 proteins was different.While these sera again reacted pref-
erentially against the HA1 proteins from the H5 viruses, particu-
larly the H5N8 and H5N3 viruses, they also displayed reactivity
against the HA1 domains of the H2 subtype. The results, further-
more, show that the breadth of the reactivity of the sera was not
affected by the glycosylation states of the immunogens used. The
sera raised against the insect cell-derived sH53
N1 appeared some-
FIG 7 Profiling HA-glycan-dependent induction of antibodies by using HA1 microarrays. (A) Mice (nine per group) were immunized twice with sH53
N1 or
sH53
N7 protein preparations produced in HEK293T cells (293T) or insect S2 cells (S2) or with HEK293S GnTI() cell-produced proteins treated with EndoH
(EndoH). Blood samples were taken 3 weeks after the second immunization. HI titers in serum against 4 HAU of sH53 for eachmouse are shown, corresponding
to the immunogen used. The horizontal lines represent the geometric means per group. Significant differences between groups are indicated as follows: *, P
0.05; **, P 0.01; ***, P 0.001. (B) An unrooted protein tree (neighbor joining) was generated from a sequence alignment (ClustalX 1.8; standard settings) of
the HA1 domains, comprising the sequence from the signal cleavage site to the HA1-HA2 proteolytic cleavage site of the 12 indicated virus strains (numbers on
right). Bootstrap values (1,000 replicates) are indicated on the branches. TheHAproteins thatwere used as immunogens are boxed; theHA1domains of the other
HA proteins were spotted on the HAmicroarray. (C andD) A panel of recombinant HA1 domains of HA proteins derived from different viruses (see panel B for
strain information) spotted in an HA1 antigen microarray format was probed with sera of mice immunized with sH53
N1 (C) or sH53
N7 (D). The titers were
defined as the interpolated serum concentration that provoked a response halfway on a concentration-response curve between the minimum and maximum
signals. Titers lower than the smallest serum dilution (1:20) were set to 20. The error bars indicate standard deviations.
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what less broadly reactive than the sera raised against the other
sH53
N1 preparations; however, this is probably explained by the
lower antibody response induced in mice immunized with the
insect cell sH53
N1 (Fig. 7A). Very similar reactivity profiles were
observed regardless ofwhethermicewere immunizedwith sH53
N7
or sH53
N1 preparations with side chains consisting of complex
glycans or single GlcNAc residues (Fig. 7C).
DISCUSSION
Recombinant soluble trimeric HA proteins provide an attractive
new means of vaccination against IAV. Glycosylation, an impor-
tant factor in the folding and (antigenic) structure of the HA pro-
tein, as well as in interaction with lectins of the immune system, is
known to be affected by the specific expression platform used.
Hence, it was of interest to study whether and to what extent the
immunogenicity of recombinant soluble HA proteins is influ-
enced by their glycosylation state. In this study, we utilized three
different cell lines and different glycan-modifying enzymes/drugs
to produce different sets of soluble trimericH5 antigens that differ
only in their glycosylation states. HA proteins produced in
HEK293T cells were shown to contain different complex-type gly-
cans. When the HA-producing HEK293T cells were treated with
KIF, theHAproteins carried only high-mannoseN-glycans with 9
mannoses. HA proteins produced in HEK293S GnTI() cells
were found to contain only high-mannose glycans containing 5
mannose moieties, while insect S2 cell-produced HA contained
different types of paucimannosidic glycans. Treatment ofHApro-
tein produced inHEK293S GnTI() cells with EndoH resulted in
HA proteins carrying single GlcNAc residues. Chickens or mice
immunized with these different purified HA preparations dis-
played different levels of HI antibody titers, indicating that the
glycosylation state of recombinant HA antigens indeed affects
their immunogenicity and is a factor of significant importance
when developing vaccines based on recombinantHAproteins and
probably more general vaccines based on glycoprotein antigens.
Our results indicate that HA proteins carrying terminal man-
nose moieties induce lower HI antibody titers in chickens and
mice than HA proteins carrying complex glycans. In a previous
study,Wei and coworkers reported that recombinantHAproteins
produced in mammalian cells are comparably or slightly more
effective in eliciting neutralizing antibodies than their insect cell-
derived counterparts (36). However, the immunogenicities of
their different HA preparations were not compared directly. Fur-
thermore, a different adjuvant, mouse strain, and HA dose were
used than in our study. Consistent with our results, increased
immunogenicity has also been observed for HIV gp120 when ter-
minal mannose moieties, which are abundantly present on gp120
proteins expressed in mammalian cells, are removed (1). In an-
other study, the antibody response against gp120 was shown to be
enhanced by occluding the mannose moieties on gp120 with grif-
fithsin (2). It was demonstrated that the terminal mannose
moieties of the N-linked glycans of HIV gp120 induce immuno-
suppressive responses in dendritic cells, which correlated with
DC-SIGN expression on these cells (30). As the HA preparations
carrying terminal mannosemoieties exhibited efficient binding to
DC-SIGN in in vitro experiments while these protein preparations
also suppressedCpG-induced IFN- release, a similarmechanism
may apply for soluble trimeric HA antigen preparations. Alterna-
tively, a role for other mannose-binding lectins, for example, in
clearance of antigens with terminal-mannose-containing glycans,
cannot be excluded (16).
The acquisition of N-linked glycosylation sites near antigenic
sites may sterically impair antibody binding to these sites (glycan
shielding) (31). The HIV gp160 protein provides a clear example
of hyperglycosylation as an effective immune escape mechanism
(24). Glycan shielding of epitopes has also been demonstrated for
HA (6, 20, 31).However, in contrast to theHIV gp160 protein, the
HA proteins are not hyperglycosylated (7, 33). This is probably
due to interference of HA glycosylation with receptor binding (9,
21, 34), thereby creating a fitness barrier to accumulating glyco-
sylation sites and providing a ready explanation for the paucity of
N-linked glycan side chains compared, for example, with HIV
gp160 (6). However, Wang and coworkers (34) recently reported
that antisera raised against H5 protein derived from an H5N1
virus bearing only single N-linked GlcNAc side chains showed
higher IAV neutralization titers than antisera elicited against HA
containing complex glycans. In agreement with these results, we
also observed higher HI titers in sera of mice immunized with
sH53
N1 proteins bearing only single N-linked GlcNAc side chains
than with those carrying complex glycans. However, the HI titers
observed for the sH53
N7 preparations were not similarly affected.
As the HA proteins in the latter preparations carry 5 rather than 6
N-glycan side chains, these results may indicate that the positive
effect of the EndoH treatment is larger for HA proteins carrying a
higher number of N-linked side chains. Alternatively, the position
of the additional N-glycan side chain in sH53
N1 at the head of the
HA protein (Fig. 2), close to the receptor binding site, may be of
particular importance.
As the HA protein sequences around the glycosylation sites
generally show less variation (6, 34), removal of (the larger part of)
the glycan side chain may be expected to result in immunogens
that induce broader immunoreactivity than their fully glycosy-
lated counterparts. The glycosylation state of the HA proteins,
however, did not affect the breadth of the antibody response as
measured with anHA1 antigenmicroarray. It will be of interest to
study whether trimming of the glycan side chains results in a
broader immune response directed against the HA2 domain,
which is more conserved than HA1. Previously, Wang and co-
workers (34) reported that immunizationwithHAproteins caring
single GlcNAc residues induced higher reactivity against HA pro-
teins of another subtype than HA protein with complex glycans.
However, as these HA preparations also induced higher reactivity
against the homologous protein, the possibility that the higher
reactivity against the nonhomologous HA proteins resulted from
intrinsically higher immunogenicity of their HA preparations
with single GlcNAc residues cannot be excluded.
Our results show that the immunogenicity of recombinant
HAs is affected by their glycosylation state and thus by the expres-
sion system used to generate these antigens. Importantly, HAs
carrying terminal mannose moieties, such as those produced in
insect cells, were shown to induce lower HI antibody titers than
other HA preparations. Although our data do not indicate that
antisera raised against HA preparations carrying single GlcNAc
side chains are more broadly reactive, at least against the HA1
domain, we conclude that the glycosylation state of recombinant
antigens is a factor of significant importance when developing
glycoprotein-based vaccines, such as recombinant HA proteins.
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